Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TQA3605 plus nucleos(t)ide analogs versus nucleos(t)ide analogs alone in previously treated chronic hepatitis B with low-level viremia
ChiCTR2500102608Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TQA3605 in Chronic Hepatitis B (CHB) (3 arms), sponsored by Ruijin Hospital. Primary endpoint: Proportion of subjects with HBV DNA below 20 IU/mL. Started May 2025; status: recruiting.
02
Drugs
TQA3605
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2500102608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102608.